


**REMARKS/ARGUMENTS**

Claims 1-8 are pending in this application and presented for examination.

Reconsideration is respectfully respected.

In the Office Action dated September 7, 2005, the Examiner requested that a single drug be elected. Applicants elect herein a drug, wherein the absorption in the gastrointestinal mucosal layer of the drug is improved by the compositions claimed herein. Applicants especially elect a drug having anti-*H. pylori* activity.

If the Examiner needs a specific species, Applicants elect compound A, on page 6, lines 7-8. More particular, Applicants elect with traverse the following disclosed species:



1-hydroxy-2-(2-trans-nonenyl)-3-methyl-4(1H)-quinolone

In their previous response, Applicants elected polyethylene glycol. In this regard, Applicants believe no undue burden exists to examine the elected species of a drug having anti-*H. pylori* activity with regard to all the compositions of Group II.


Under M.P.E.P. § 821.04, if Applicants elect claims directed to the product, and the product claims are allowable, withdrawn process claims which depend from or otherwise include all the limitations of the allowable product claims must be rejoined. Process claims, which depend from, or otherwise include all the limitations of the patentable product, will be entered as a matter of right.

Appl. No. 10/672,398  
Amdt. dated October 27, 2005  
Reply to Office Action of September 7, 2005

PATENT

In view of the foregoing, Applicants respectfully request early action on the merits. If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,



Joseph R. Snyder  
Reg. No. 39,381

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 925-472-5000  
Fax: 415-576-0300  
JS:js  
60609214 v1